DK0548949T5 - Kondenserede benzenoxyeddikesyrederivater - Google Patents

Kondenserede benzenoxyeddikesyrederivater

Info

Publication number
DK0548949T5
DK0548949T5 DK92121898T DK92121898T DK0548949T5 DK 0548949 T5 DK0548949 T5 DK 0548949T5 DK 92121898 T DK92121898 T DK 92121898T DK 92121898 T DK92121898 T DK 92121898T DK 0548949 T5 DK0548949 T5 DK 0548949T5
Authority
DK
Denmark
Prior art keywords
chem
alkyl
acetic acid
acid derivatives
condensed benzene
Prior art date
Application number
DK92121898T
Other languages
English (en)
Other versions
DK0548949T3 (da
Inventor
Nobuyuki Hamanaka
Kanji Takahashi
Hidekado Tokumoto
Hamanaka Nobuyuki
Takahashi Kanji
Tokumoto Hidekado
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP3360502A external-priority patent/JPH05178832A/ja
Priority claimed from JP4209587A external-priority patent/JPH0725854A/ja
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of DK0548949T3 publication Critical patent/DK0548949T3/da
Application granted granted Critical
Publication of DK0548949T5 publication Critical patent/DK0548949T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK92121898T 1991-12-27 1992-12-23 Kondenserede benzenoxyeddikesyrederivater DK0548949T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3360502A JPH05178832A (ja) 1991-12-27 1991-12-27 縮合ベンゼンオキシ酢酸誘導体
JP4209587A JPH0725854A (ja) 1992-07-14 1992-07-14 縮合ベンゼンオキシ酢酸誘導体

Publications (2)

Publication Number Publication Date
DK0548949T3 DK0548949T3 (da) 1998-03-30
DK0548949T5 true DK0548949T5 (da) 1998-11-23

Family

ID=26517547

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92121898T DK0548949T5 (da) 1991-12-27 1992-12-23 Kondenserede benzenoxyeddikesyrederivater

Country Status (11)

Country Link
US (4) US5389666A (da)
EP (1) EP0548949B1 (da)
JP (1) JP3419009B2 (da)
KR (1) KR0148389B1 (da)
AT (1) ATE158282T1 (da)
CA (1) CA2085844A1 (da)
DE (1) DE69222280T2 (da)
DK (1) DK0548949T5 (da)
ES (1) ES2108076T3 (da)
GR (1) GR3024771T3 (da)
TW (1) TW221291B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) * 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
IT1265209B1 (it) * 1993-11-22 1996-10-31 Pierrel Spa Difenilimidazoli utili nel trattamento di dislipidemia, arteriosclerosi e malattie coronariche procedimento per la loro
WO1996018602A1 (en) * 1994-12-13 1996-06-20 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
CN1092639C (zh) 1995-01-06 2002-10-16 东丽株式会社 苯稠合杂环衍生物及其用途
US6407096B1 (en) * 1998-08-04 2002-06-18 Toray Industries, Inc. Benzene fused heterocyclic derivatives having thromboxane A2 receptor antagonistic activity and prostaglandin I2 Agonistic activity and application thereof
US6781288B2 (en) * 1999-01-27 2004-08-24 Bae Systems Information And Electronic Systems Integration Inc. Ultra-low frequency acoustic transducer
KR20020015345A (ko) * 1999-06-21 2002-02-27 후지야마 아키라 피부 궤양 치료제
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
ES2373875T3 (es) * 2002-03-05 2012-02-09 Transtech Pharma, Inc. Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage.
FR2846328B1 (fr) * 2002-10-23 2004-12-10 Servier Lab Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU2004251599A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
EA019882B1 (ru) 2008-03-18 2014-07-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора простациклина (pgi2), пригодные для лечения связанных с ним расстройств
US20110224262A1 (en) * 2008-11-26 2011-09-15 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
PL2370413T3 (pl) 2008-12-08 2016-01-29 Arena Pharm Inc Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
CN107106532A (zh) 2014-10-23 2017-08-29 艾尼纳制药公司 治疗与pgi2受体相关的病症的方法
MA47686A (fr) 2017-03-01 2021-05-12 Arena Pharm Inc Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
US4368332A (en) * 1979-01-05 1983-01-11 National Research Development Corporation Prostaglandins
ZA814307B (en) * 1980-07-01 1983-02-23 Nat Res Dev Prostaglandins
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
FR2498382A1 (fr) * 1981-01-16 1982-07-23 Commissariat Energie Atomique Connecteur electrique
JPS57150667A (en) * 1981-02-12 1982-09-17 Wellcome Found Antithrombotic
US4492708A (en) * 1982-09-27 1985-01-08 Eli Lilly And Company Antiviral benzimidazoles
DE3504677A1 (de) * 1985-02-12 1986-08-14 A. Nattermann & Cie GmbH, 5000 Köln Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2003283A1 (en) * 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
US5011851A (en) * 1990-02-13 1991-04-30 Bristol-Myers Squibb Co. Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2036192A1 (en) * 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2085844A1 (en) * 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
JP2556418B2 (ja) * 1992-07-14 1996-11-20 大光炉材株式会社 不定形耐火材

Also Published As

Publication number Publication date
GR3024771T3 (en) 1997-12-31
US5589496A (en) 1996-12-31
EP0548949A3 (en) 1993-10-06
KR0148389B1 (ko) 1998-11-02
EP0548949A2 (en) 1993-06-30
CA2085844A1 (en) 1993-06-28
US5962439A (en) 1999-10-05
JPH07145057A (ja) 1995-06-06
TW221291B (da) 1994-02-21
DK0548949T3 (da) 1998-03-30
DE69222280D1 (de) 1997-10-23
JP3419009B2 (ja) 2003-06-23
ATE158282T1 (de) 1997-10-15
US5389666A (en) 1995-02-14
US5849919A (en) 1998-12-15
ES2108076T3 (es) 1997-12-16
DE69222280T2 (de) 1998-03-05
EP0548949B1 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
DK0548949T3 (da) Kondenserede benzenoxyeddikesyrederivater
AU7930887A (en) Phenylpyrazolecarboxylic acid derivatives, their preparation, and their use as plant-growth regulators and safeners
FI102535B1 (fi) Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 1,3,5-trisubstituoituja pyratsolijohdannaisia
ES2103989T3 (es) Derivados de acido fenoxiacetico y composiciones farmaceuticas que los contienen.
IL110703A0 (en) Intermediates to 4-benzoyl isoxazole derivatives
FI103508B1 (fi) Menetelmä anti-inflammatorisen aktiivisuuden omaavien 2-substituoitujen tiatsolidinonien, oksatsolidinonien ja imidatsolidinonien 3,5-di-tert.butyyli-4-hydroksifenyylimetyleenijohdannaisten valmistamiseksi
HK1029338A1 (en) Intermediates for the preparation of oxazolidinedione and thiazolidinedione derivatives
NL300407I2 (nl) Difluoroprostaglandinederivaten en hun toepassing
OA09391A (en) "Isoxazole derivatives".
FI893467A0 (fi) Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi
EP0542203A3 (en) Fused benzeneoxyacetic acid derivatives as pgl2 receptor agonists
MX9606305A (es) Productos de proteccion de cultivos.
KR910019988A (ko) 피페리딜옥시-및 퀴누클리디닐옥시-이소옥사졸 유도체, 그의 제조방법 및 치료적 용도
FI881104A0 (fi) Menetelmä antidiabeettisina aineina käytettävien bentsoksatsiinijohdannaisten valmistamiseksi
DE69204908T2 (de) 2-Hydroxy-2-phenylethylaminderivate als Beta-3-adrenoceptor Agonisten.
DK0451538T3 (da) Anvendelse af pyridoindolderivater til behandling af iskæmiske lidelser
NO911149D0 (no) Fremgangsmaate for fremstilling av merkaptan- og merkaptoacyl-derivater.
DK0534655T3 (da) Thiazolidin-2,4-dioner til behandling af hypertension
ATE71364T1 (de) Fluor enthaltende vitamin-d2-derivate.